Overview of Mouse Models of Parkinson's Disease
Open Access
- 3 September 2014
- journal article
- research article
- Published by Wiley in Current Protocols in Mouse Biology
- Vol. 4 (3) , 121-139
Abstract
Parkinson's disease is a neurodegenerative disorder characterized by the loss of neurons in specific regions of the nervous system, notably in the substantia nigra pars compacta and, in most cases, by the deposition of intraneuronal inclusions named Lewy bodies. These pathological alterations have profound effects on the brain function, leading to the progressive development of various symptoms, the most prominent being the impaired initiation of voluntary movements caused by the loss of dopamine signaling in the basal ganglia. Here, we provide an overview of the mouse models of Parkinson's disease, with the goal of guiding selection of the most appropriate model for studying the question at hand. Pharmacological approaches targeting dopamine signaling and toxins leading to selective degeneration of nigral neurons are used to validate symptomatic treatments that aim at restoring effective dopaminergic function for motor control. Alternative mouse models are based on genetic modifications that are meant to reproduce the inherited alterations associated with familial forms of Parkinson's disease. Although genetic models have most often failed to induce overt degeneration of nigral dopaminergic neurons, they provide essential tools to explore the multifactorial etiology of this complex neurodegenerative disorder.Curr. Protoc. Mouse Biol. 4:121‐139 © 2014 by John Wiley & Sons, Inc.Keywords
This publication has 76 references indexed in Scilit:
- A Progressive Mouse Model of Parkinson's Disease: The Thy1-aSyn (“Line 61”) MiceNeurotherapeutics, 2012
- PINK1 and Parkin Target Miro for Phosphorylation and Degradation to Arrest Mitochondrial MotilityCell, 2011
- Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's diseaseNature Medicine, 2010
- Genetic Animal Models of Parkinson's DiseaseNeuron, 2010
- Mutant LRRK2R1441G BAC transgenic mice recapitulate cardinal features of Parkinson's diseaseNature Neuroscience, 2009
- Loss of enteric dopaminergic neurons and associated changes in colon motility in an MPTP mouse model of Parkinson's diseaseExperimental Neurology, 2007
- Lack of nigrostriatal pathology in a rat model of proteasome inhibitionAnnals of Neurology, 2006
- Proteasome inhibition and Parkinson's disease modelingAnnals of Neurology, 2006
- α-Synuclein Cooperates with CSPα in Preventing NeurodegenerationCell, 2005
- Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's diseaseAnnals of Neurology, 2004